博士毕业于中国科学院上海药物研究所，长期致力于骨髓瘤等肿瘤领域的蛋白质结构与功能的研究，并综合运用结构生物学、计算机辅助药物设计等多学科交叉的技术手段开展大分子与小分子药物的早期研发。以第一/通讯作者发表SCI论文15篇，包括Cell Discov（2022，2020，2017）以及计算化学经典老牌杂志J Chem Inf Model（2023，2017）和药物化学经典杂志Eur J Med Chem（2015）等。授权和申请化合物发明专利4项。主持国家自然科学基金两项（国自然面上（在研）、国自然青年（结题））。
She was graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. She has foused on the study of protein structure and function in myeloma and other cancers, and combined structural biology, computer-aided drug design and other technologies to develop macromolecular and small molecule drugs. She has published 15 SCI papers as first/corresponding author, including Cell Discov (2022, 2020, 2017) as well as classic journals of computational chemistry and medicinal chemistry, such as J Chem Inf Model (2023, 2017) and Eur J Med Chem (2015), etc. Authorised two patents for compound inventions. Supported by two research grants from National Natural Science Foundation of China.
【近五年代表性文章】
[1] X. Gao, Q. Feng, Q. Zhang, Y. Zhang, C. Hu, L. Zhang, H. Zhang, G. Wang, K. Hu, M. Ma, Z. Wang, Y. Liu, D. An, H. Yi, Y. Peng, X. Wu, G. Chen, X. Jia, H. Cai, J. Shi, Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis, J Biomed Sci, 32 (2025) 9.
[2] K. Hu, Y. Lai, J. Zhou, C. Hu, S. Guo, H. Zhang, G. Wang, Q. Zhang, X. Gao, Z. Wang, Y. Liu, Q. Feng, H. Yi, Y. Peng, Y. Zhang, X. Wu, H. Cai, J. Shi, Aberrant activation of adenine nucleotide translocase 3 promotes progression and chemoresistance in multiple myeloma dependent on PINK1 transport, Int J Biol Sci, 21 (2025) 233-250.
[3] Y. Lai, S. Guo, Q. Tang, G. Chang, H. Zhang, B. Li, Q. Feng, K. Hu, Z. Xu, X. Gao, Q. Zhang, H. Yi, D. Song, Y. Zhang, Y. Peng, H. Cai, W. Zhu, J. Shi, Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphoma, Arch Biochem Biophys, 754 (2024) 109929.
[4] S. Jacob Bunu, H. Cai, L. Wu, H. Zhang, Z. Zhou, Z. Xu, J. Shi, W. Zhu, TRIP13 - a potential drug target in cancer pharmacotherapy, Bioorg Chem, 151 (2024) 107650.
[5] S. Guo, Q. Tang, X. Gao, L. Hu, K. Hu, H. Zhang, Q. Zhang, Y. Lai, Y. Liu, Z. Wang, S. Chang, Y. Zhang, H. Hu, D. An, Y. Peng, H. Cai, J. Shi, EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma, Acta Biochim Biophys Sin (Shanghai), 56 (2024) 1055-1064.
[6] H. Cai, Y. Wang, J. Zhang, Z. Wei, T. Yan, C. Feng, Z. Xu, A. Zhou, Y. Wu, Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells, J Chem Inf Model, 63 (2023) 4780-4790.
[7] J. Zhang, X. Jiang, H. Gao, F. Zhang, X. Zhang, A. Zhou, T. Xu, H. Cai, Structural Basis of a Novel Agonistic Anti-OX40 Antibody, Biomolecules, 12 (2022).
[8] Z. Shu, J. Zeng, L. Xia, H. Cai, A. Zhou, Structural mechanism of VWF D'D3 dimer formation, Cell Discov, 8 (2022) 14.
[9] H. Cai, P. Sasikumar, G. Little, D. Bihan, S.W. Hamaia, A. Zhou, J.M. Gibbins, R.W. Farndale, Identification of HSP47 Binding Site on Native Collagen and Its Implications for the Development of HSP47 Inhibitors, Biomolecules, 11 (2021).
[10] H. Gao, H. Cai, J. Liu, X. Wang, P. Zheng, M. Devenport, T. Xu, F. Dou, Y. Liu, A. Zhou, Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody, Cell Discov, 6 (2020) 79.
